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biomarker for irritable bowel syndrome?
Per G. Farup1,2*, Knut Rudi3 and Knut Hestad1,4,5
Abstract
Background: The diagnosis of irritable bowel syndrome (IBS) relies on symptom-based criteria. A valid and reliable
biomarker that could confirm the diagnosis is desirable. This study evaluated the properties of faecal short-chain
fatty acids (SCFA) as diagnostic biomarkers for IBS.
Methods: Twenty-five subjects with IBS and 25 controls were included in this explanatory case–control study. Stool
samples were analysed for SCFA (acetic acid, propionic acid, butyric acid, isobutyric acid, valeric acid, and isovaleric
acid) with gas chromatography and reported as mmol/l and molar%. In the search for the best way to distinguish
between subjects with and without IBS, the total amount and the amount of each of the SCFA were measured,
and the proportions and differences between the SCFA were calculated.
Results: In the IBS and control group, the mean age was 46.2 (SD 12.9) and 49.2 (SD 14.6), and the number of
females was 13/25 (52 %) and 15/25 (60 %) respectively. The difference between propionic and butyric acid (mmol/
l) had the best diagnostic properties, the area under the Receiver Operating Characteristic curve was 0.89 (95 % CI:
0.80–0.98) (p < 0.001). With a cut-off value > 0.015 mmol/l indicating IBS, the sensitivity, specificity, positive and
negative likelihood ratio, and diagnostic odds ratio were 92 %, 72 %, 3.29, 0.11 and 29.6 respectively. Similar
diagnostic properties were shown for all the IBS subgroups.
Conclusions: The study indicated that faecal SCFA could be a non-invasive, valid and reliable biomarker for the
differentiation of healthy subjects from subjects with IBS.
Background
Irritable bowel syndrome (IBS) is a common functional
gastrointestinal disorder [1, 2]. The diagnosis is based on
internationally accepted symptom-based criteria (the
Rome criteria) after exclusion of organic diseases [3].
Since multiple disorders have similar symptoms, a valid
and reliable diagnostic biomarker for IBS has been
highly demanded. Physicians often avoid setting a posi-
tive diagnosis of IBS without extensive investigations.
Clarke et al.’s statement in 2009 has the same actuality
today: “The successful identification of biomarkers is
critical to progressing our understanding of IBS and ad-
dressing the unmet therapeutic needs of this debilitating
condition” [4].
Extensive research has been carried out to find valid
and reliable biomarkers for IBS. Several biomarkers
separate IBS from organic diseases (e.g. Inflammatory
Bowel Disease) and healthy volunteers, but so far
none has been judged as satisfactory for the use in
daily practice [5, 6].
The association between IBS and the gut microbiota
has been demonstrated in several studies and efforts
have been made to characterise the abnormal microbiota
in patients with IBS [7, 8]. So far, the results have been
inconsistent. For the human health and disease, the
function of the microbiota might, therefore, be as im-
portant as the phylotype. It has been argued that “the
phylotype provides the environmentally selected inter-
face for the functions”[9]. The function could be mea-
sured as chemicals and metabolites in the faeces. The
microbiota metabolises non-digestible food constituents
into short-chain fatty acids (SCFA) that have extensive
immunological and regulatory functions and appear to
be the link in the host-microbe interactions [10–13].
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SCFA and functional bowel disorders has not been ex-
tensively investigated. The immunological activation
often seen in subjects with IBS could be associated with
the changes in SCFA [11, 14–17]. In one study, volatile
organic metabolites showed promising diagnostic prop-
erties for IBS [16].
The aims of this case–control study were to compare
faecal SCFA in subjects with and without IBS and search
for biomarkers that could aid in differentiating patients
with IBS from healthy subjects.
Methods
Design
This study was an add-on to a previous study comparing
patients with depression and unspecified neurological
symptoms [18, 19]. Fifty patients, 25 with IBS and 25 with-
out, were arbitrarily selected for this case–control study.
Participants
In the previous study, patients above 17 years of age
with the diagnosis of idiopathic depression (according to
ICD-10; F 32–34 spectre) were included in the “depres-
sion group”. Patients admitted to an inpatient neuro-
logical clinic with unexplained neurological symptoms
were included in the “neurological group”. In both
groups, organic diseases were excluded after comprehen-
sive clinical, laboratory, and supplementary investiga-
tions according to the doctors’ discretion. In the
neurological group, the examinations included a thor-
ough neurological examination, analysis of the cerebro-
spinal fluid and either a cerebral CT or MRI scan.
Subjects with excessive alcohol intake were excluded. In-
clusion and exclusion criteria, design and methods have
been described in detail in previous papers [18, 19].
Variables
Demographics: Gender; Age (years); education (number
of years in school).
Abdominal complaints: IBS (yes/no) according to the
Rome III criteria was assessed with a validated Norwe-
gian translation of the Rome-questionnaire [3].
Depression: Beck Depression Inventory v. II (BDI II)
(minimal, mild, moderate and severe depression;
scores 0–13, 14–19, 20–28 and 29–63 respectively)
[20]. Montgomery-Åsberg Depression Scale (MADRS):
(symptom absent, mild, moderate and severe depression;
scores 0–6, 7–19. 20–34 and 35–60 respectively) [21].
Faecal samples: Stool samples were analysed for short-
chain fatty acids (acetic acid, propionic acid, butyric acid,
isobutyric acid, valeric acid, and isovaleric acid) with gas
chromatography as described by Szczesniak et al. [22]. The
amounts of SCFA have been reported as mmol/l and
molar%. In the search for the best way to distinguishsubjects with and without IBS, the amount of SCFA
and the proportion and differences between the SCFA
were used.
Statistics
The exact chi-square test and Student t-test were used
for the comparisons between the groups, and non-
parametric statistics was used in addition for variables
without normal distribution. Linear multiple regression
was used to study independent predictors. The diagnos-
tic properties were assessed with Receiver Operating
Characteristics (ROC) curves, sensitivity, specificity,
positive- and negative Likelihood Ratio (LR) and Diag-
nostic Odds Ratio (DOR). P-values below 0.05 were
judged as statistically significant.
Ethics
The study was approved by the Norwegian Regional
Committees for Medical and Health Research Ethics, PB
1130, Blindern, 0318 Oslo, Norway (reference number
2009/2196a) and performed in accordance with the
Declaration of Helsinki. Written informed consent was
given by all participants before inclusion.
Results
Participants
Twenty-five Caucasian subjects with IBS and 25 without
were included in the study. Table 1 gives the characteris-
tics of the subjects. No patients were excluded from the
study due to an organic disorder that could explain the
IBS-like symptoms, and none used antibiotics. The
number of subjects with constipation-predominant IBS
(IBS-C), diarrhoea-predominant IBS (IBS-D), mixed IBS
(IBS-M) and undefined IBS (IBS-U) was 8, 9, 7 and 1 re-
spectively. Except for higher scores for depression in the
IBS group than in the control group, the groups were well
balanced. The imbalance in the degree of depression oc-
curred by chance and was due to a higher proportion of
subjects from the “depression group” in the IBS group
(19/25; 76 %) than in the control group (14/25; 56 %).
SCFA
Table 2 gives the results of the SCFA with comparisons
between subjects with and without IBS. Butyric acid
(molar%) was statistically significantly higher in the con-
trol group, and there was a non-significant trend toward
a higher concentration of propionic acid (mmol/l and
molar%) in the IBS group. Therefore, the propionic/bu-
tyric ratio and the differences between propionic acid
and butyric acid (Prop-But) were calculated. They
showed highly statistically significant differences be-
tween the groups. The best one for the discrimination
between subjects with and without IBS turned out to be
Prop-But (mmol/l). This variable also showed statistically
Table 1 The participants’ characteristics
Characteristics IBS (no 25) Control (no 25) Statistics (p-values)
Gender (female/male) 13 (52 %)/12 (48 %) 15 (60 %)/10 (40 %) ns (p = 0.78)
Age (years) 46.2 (12.9) 49.2 (14.6) ns (p = 0.45)
Group (depression/neuro) 19 (76 %)/6 (24 %) 14 (56 %)/11 (44 %) ns (p = 0.23)
Education (years) 13.0 (2.8) 13.1 (2.5) ns (p = 0.83)
BDI II (score) 26.7 (15.6) 14.2 (9.5) p = 0.001
MADRS (score) 24.8 (11.4) 15.5 (9.4) p = 0.003
The results are given as the number with proportion (%) in brackets and mean with SD in brackets
BDI II Beck Depression Inventory v. II
MADRS Montgomery-Åsberg Depression Scale
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(IBS-C, IBS-D and IBS-M) and the control group
(Table 3).
The imbalance between the groups concerning depres-
sion made it necessary to control for confounding. A
linear regression analysis with Prop-But as the dependent
variable, and group (IBS/control) and BDI II as covariates
was performed. IBS, but not BDI II was an independent
predictor of Prop-But; standardised beta and p-values
were 0.55, p < 0.001; and - 0.01, p = 0.92; respectively.
Diagnostic properties of SCFA
The differences between subjects with and without IBS
were highly statistically significant for the “Propionic
acid/Butyric acid ratio” and “Propionic acid minus Bu-
tyric acid (mmol/l and molar%)” (Prop-But) (Tables 2
and 3). Prop-But (mmol/l) showed the best diagnosticTable 2 Faecal short-chain fatty acids in subjects with and without
Short-chain fatty acids (SCFA) IBS (no 25)
The sum of SCFA (mmol/l) 10.54 (9.14)
Acetic acid (mmol/l) 6.42 (6.29)
Propionic acid (mmol/l) 1.93 (1.43)
Butyric acid (mmol/l) 1.56 (1.25)
Iso-Butyric acid (mmol/l) 0.17 (0.10)
Valeric acid (mmol/l) 0.19 (0.13)
Iso-Valeric acid (mmol/l) 0.25 (0.13)
Acetic acid (molar%) 56.26 (7.56)
Propionic acid (molar%) 20.20 (4.95)
Butyric acid (molar%) 15.58 (2.75)
Iso-Butyric acid (molar%) 2.21 (1.07)
Valeric acid (molar%) 2.25 (0.74)
Iso-Valeric acid (molar%) 3.50 (2.04)
Propionic – Butyric acid (mmol/l) 0.36 (0.34)
Propionic – Butyric acid (molar%) 4.61 (5.22)
Propionic/Butyric mmol/l ratio (%) 132 % (37 %)
The results are given as mean values with SD in brackets. The Student T-test was us
normally distributed. Analyses with non-parametric statistics (Mann–Whitney U-testproperties. Figure 1 shows the diagnostic property of
Prop-But (mmol/l) presented as the Receiver Operating
Characteristics (ROC) curve. The area under the curve
(AUC) was 0.89 (95 % CI 0.80: 0.98), p < 0.001. A Prop-
But value > 0.015 was judged as a well-suited cut-off for
a positive test for IBS and was used in the calculation of
the diagnostic properties. Table 4 gives the diagnostic
properties of Prop-But (mmol/l) (AUC, sensitivity, speci-
ficity, positive- and negative likelihood ratio and diag-
nostic odds ratio) for all patients and for each of the IBS
subgroups. A Prop-But value < - 0.13 excluded IBS (the
sensitivity was 100 %), and a value > 0.46 confirmed the
diagnosis of IBS (the specificity was 100 %).
Discussion
There is a pressing need for a good biomarker for IBS.
The list of attempts to find a suitable biomarker is longIBS with comparisons between the groups
Control (no 25) Statistics (p-values)
8.36 (7.57) ns (p = 0.36)
4.81 (4.98) ns (p = 0.32)
1.34 (0.98) ns (p = 0.10)
1.67 (1.56) ns (p = 0.80)
0.15 (0.12) ns (p = 0.52)
0.17 (0.13) ns (p = 0.42)
0.22 (0.14) ns (p = 0.34)
55.48 (8.23) ns (p = 0.73)
17.85 (3.94) ns (p = 0.07)
19.00 (4.55) p = 0.003
2.10 (1.42) ns (p = 0.75)
2.08 (1.00) ns (p = 0.49)
3.50 (1.98) ns (p = 0.99)
- 0.32 (0.69) p < 0.001
- 1.15 (5.46) p < 0.001
98 % (27 %) p < 0.001
ed for the comparisons between the groups. Several of the variables were not
) showed principally identical results (data not shown)
Table 3 The “Propionic minus Butyric acid (mmol/l)” values in
the subgroups of subjects with IBS and comparisons with the
control group
IBS subtype Propionic minus Butyric acid Statistics p-value
IBS Control
IBS-C (no 8) 0.21 (0.24) - 0.32 (0.69) p = 0.04
IBS-D (no 9) 0.51 (0.37) - 0.32 (0.69) p = 0.002
IBS-M (no 7) 0.37 (0.37) - 0.32 (0.69) p = 0.016
IBS-U (no 1) 0.24 (−−-) - 0.32 (0.69) ns (p = 0.43)
Abbreviations: IBS-C: Constipation-predominant IBS; IBS-D: Diarrhoea-
predominant IBS; IBS-M: Mixed IBS; IBS-U: Undefined IBS. No: Number
of subjects
The results are given as mean values with SD in brackets. The Student T-test
was used for the comparisons between the groups. Several of the variables
were not normally distributed. Analyses with non-parametric statistics
(Mann–Whitney U-test) showed principally identical results (data not shown)
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resulted in a tool for use in daily practice [5, 6]. It was
recently stated that no tool has surpassed the symptom-
based criteria [5]. This study indicated that faecal
SCFA could be a valuable diagnostic biomarker for
IBS. With the chosen cut-off value, a negative test
nearly excluded IBS.
The evidence for an association between the gut
microbiota and IBS is increasing, at least in a subpopula-
tion of the patients [7, 8, 23]. The microbiota is pre-
sumed to induce pathophysiological reactions such as
activation of the mucosal immune system, increased in-
testinal permeability, activation of sensory pathways, and
modulation of the enteric motility. Several studies show
differences, but not the same differences, between the
microbiota in patients with IBS and healthy volunteers
and between subgroups of patients with IBS [8]. The
findings indicate an imbalance of the microbiota (dysbio-
sis) in subjects with IBS, but a precise description of the
imbalance has so far not been successful.
Knowledge of the function of the microbiota might be
as relevant as knowledge of the microbiota itself and
might add diagnostic and mechanistic insight to the
study of the composition of the microbiota [12, 13, 23].
SCFA are produced by the microbiota trough fermenta-
tion of ingestible polysaccharides and proteins, and have
been described as the link between the microbes and the
host [10, 11]. SCFA have anti-inflammatory effects by
modulation of the immune cell chemotaxis, and the re-
lease of reactive oxygen species (ROS) and cytokines
[10]. The effects are mediated mainly by inhibition of
histone deacetylases (HDACs) and stimulation of G-
protein-coupled receptors (GPCRs), particularly GPR43
[10, 12]. IBS might be an inflammatory disorder. Studies
in subjects with IBS have shown an activation of the im-
mune system and an imbalance in the cytokine pattern
[14, 15]. The lack of association between the totalamount of SCFA in subjects with and without IBS seen
in this and other studies could be due to different and
opposite effects of the SCFA [11, 23–26]. The exact
pathophysiology of IBS is unknown, and the absolute
and relative amount of each of the SCFA might be more
important than the total amount of SCFA. Butyrate,
which is a key promoter of colonic health and the main
provider of energy for the colonocytes, inhibits Il-12 and
increases Il-10 production, and has a beneficial effect in
various disorders [11, 13, 27]. Propionate is a potent ac-
tivator of GPR43 that is present in immune, nervous and
endocrine cells along the entire gastrointestinal tract
[10]. The effects of the SCFA vary significantly, and the
variation in absolute and relative amount could explain
the seemingly different associations between SCFA and
diseases [11–13]. The unfavourable effect of propionic
acid in subjects with IBS, and the reverse effects of pro-
pionic and butyric acid have been reported in some but
not all studies [23–26]. The discrepancies between the
studies could be caused by dietary variations such as
variation in the intake of FODMAPs [17]. The findings
in this study and other studies indicate that SCFA, par-
ticularly the relation between propionate and butyrate,
could be a diagnostic biomarker of IBS.
In this study, SCFA showed very satisfactory diag-
nostic properties for the diagnosis of IBS. The best
parameter was Prop-But (mmol/l) with AUC = 0.89,
sensitivity 92 % and specificity 72 %. The results seem
to be as good as other diagnostic tools, but compari-
sons are difficult [5, 6].
A test’s diagnostic properties depends on the reference
standard (the gold standard), the aim of the test, and the
population. No gold standard exists. In this study, the
reference standard was the Rome III criteria after exclu-
sion of organic diseases. Most studies have used
symptom-based criteria (e.g. Manning, Rome I, II and
III) with a more or less complete exclusion of organic
diseases [16, 28–31]. Other studies (like the one that val-
idated the Rome III criteria) have used a not standar-
dised definition [32]. The use of different reference
standards makes comparisons of diagnostic tests for IBS
nearly impossible.
Also, the aims of other studies have varied. Some studies
aimed at separating patients with IBS-symptoms and or-
ganic diseases (like IBD) from patients with true IBS, some
aimed at separating patients with IBS from healthy sub-
jects, and some aimed at distinguishing subtypes of IBS
[16, 28–31, 33]. The test results with one diagnostic
marker vary depending on the aim of the study, as clearly
shown by Ahmed et al. [16]. Most markers only dif-
ferentiate IBS from organic diseases and not from
healthy volunteers. At last, the participants in other
studies have been selected from different populations,
e.g. the general population, primary, secondary and
Fig. 1 The diagnostic properties of Propionic – Butyric acid (mmol/l) presented as the Receiver Operating Characteristic curve
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and degree of symptoms; and patients with various
organic disorders [16, 29, 31]. Comparisons of the re-
sults from studies of tests for the diagnosis IBS are
unreliable without a strict control for the gold stand-
ard, the aims of the studies and the populations in
the studies. Heterogeneity and design-related bias
make comparisons of studies of diagnostic tests
difficult [34, 35].Table 4 The diagnostic properties of “Propionic acid minus Butyric a
subgroups of IBS
IBS group AUC (95 % CI) Significance S
IBS (all subjects) 0.89 (0.80:0.98) p < 0.001 9
IBS-C (no 8) 0.83 (0.67:0.99) p = 0.006 8
IBS-D (no 9) 0.92 (0.78:1.00) p < 0.001 8
IBS-M (no 7) 0.91 (0.81:1.00) p = 0.001 1
IBS-U (no 1) 0.92 (0.81:1.00) ns (p = 0.16) 1
Abbreviations: IBS-C: Constipation-predominant IBS; IBS-D: Diarrhoea-predominant IB
Confidence interval; Sens.: Sensitivity; Spec: Specificity; Pos. LH: Positive Likelihood RAhmed et al. have studied the diagnostic accuracy
of faecal volatile organic metabolites in IBS and
showed that the results depended on the aim [16].
When the aim was to differentiate IBS from healthy
individuals, as it was in the actual study, the sensitiv-
ity and specificity of the test were 90 and 80 % re-
spectively. In the actual study, the marker was a
simple difference between two SCFA, whereas Ahmed
et al. used a complex discriminatory model [16]. Testscid (mmol/l)” for the diagnosis of IBS in all subjects and the
ens Spec Pos. LR Neg. LR DOR
2 % 72 % 3.29 0.11 29.6
7.5 % 72 % 3.13 0.17 18.0
9 % 72 % 3.17 0.15 20.6
00 % 72 % 3.57 0.00 NA
00 % 72 % 3.57 0.00 NA
S; IBS-M: Mixed IBS; IBS-U: Undefined IBS; AUC: Area Under the Curve; CI:
atio; Neg. LR: Negative Likelihood Ratio; DOR: Diagnostic Odds Ratio
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test battery, complex calculations, colonic transit time
and faecal bile acid) have not been proven to be bet-
ter than the more simple ones [16, 28–31].
Strengths and limitations
The results of this small study were promising. If the
measurement of SCFA in faeces turns out to be a valu-
able biomarker for IBS, it will be a simple test without
invasive procedures and complicated calculations. The
external validity of the actual study might be questioned
since the subjects were recruited from a study compar-
ing subjects with depression and unspecified neuro-
logical symptoms. However, the multivariable analyses
did not indicate any confounding effects. Information
about the diet, which has been shown to influence on
the faecal microbiota, could have improved the study
[17]. Neither was smoking habits recorded. The study
evaluated only the diagnostic ability to differentiate IBS
from healthy volunteers, and not IBS from organic dis-
eases. Because the study had an exploratory design and a
limited number of participants, the results need con-
firmation in a new, larger and hypotheses driven valid-
ation study.
Conclusions
The study indicated that faecal SCFA could be a non-
invasive, valid and reliable biomarker for the differenti-
ation of IBS from healthy volunteers, particularly for the
exclusion of the diagnosis.
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